Hoth Therapeutics Inc

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for unmet medical needs in the United States. Its pipeline includes HT-001, a topical formulation in Phase II for rash and skin disorders associated with tyrosine kinase EGFR inhibitor therapy; HT-KIT for mast-cell derived cancers and anaphylaxis; HT-TBI for traumatic brain injury and ischemic stroke; HT-ALZ for Alzheimer's and other neuroinflammatory diseases; and HT-004 for asthma and allergies via inhalation. The company is also developing the BioLexa Platform, a patented drug compound platform in Phase I for eczema, and HT-005 for lupus. It has license agreements with George Washington University, Isoprene Pharmaceuticals, North Carolina State University, Chelexa BioSciences and the University of Cincinnati, Zylö Therapeutics, and Voltron Therapeutics. Incorporated in 2017, it is based in Hoboken, New Jersey.